Quinidine; Natisedine/Selected QT Prolongers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Quinidine, which is also a component of natisedine, can affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
Taking quinidine or natisedine with other agents that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Saphris (asenapine) US prescribing information. Schering Corporation October, 2011.
2.Procoralan (ivabradine hydrochloride) summary of product characteristics. Servier December, 2005.
3.Serentil (mesoridazine besylate) US prescribing information. Novartis Pharmaceuticals Corporation August, 2000.
4.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation June, 2013.
5.Invega (paliperidone) US prescribing information. Janssen Pharmaceuticals, Inc. April, 2011.
6.Seroquel (quetiapine fumarate) US prescribing information. AstraZeneca Pharmaceuticals LP July, 2011.
7.Qualaquin (quinine sulfate) US prescribing information. AR Scientific, Inc. April, 2013.
8.Javlor (vinflunine ditartrate) UK Summary of Product Characteristics. Pierre Fabre Limited September 21, 2009.
9.Clopixol (zuclopenthixol acetate) UK summary of product characteristics. Lundbeck House October 24, 2008.
10.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP July, 2013.
11.Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) US prescribing information. Avanir Pharmaceuticals August, 2011.
12.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
13.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
14.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.